Market Place
Sourcing Support
EC Approves Pfizer’s HYMPAVZI™ for Severe Hemophilia A/B
20 Nov 2024 //
BUSINESSWIRE
Pfizer`s Biologic Hympavzi (Marstacimab-hncq) Receives Approval in US
11 Oct 2024 //
FDA
FDA and EMA Accept Marstacimab Regulatory Submissions for Hemophilia A and B
11 Dec 2023 //
BUSINESSWIRE
Pfizer presents marstacimab Phase 3 Data at ASH 2023
10 Dec 2023 //
INDIAN PHARMA POST
Marstacimab Phase 3 Data Presented Showes Bleed Reduction in Hemophilia A and B
09 Dec 2023 //
BUSINESSWIRE
Pfizer Announces +VE Marstacimab Results from Pivotal Ph3 Hemophilia A & B Trial
30 May 2023 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.